CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kanabo Group PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kanabo Group PLC
Churchill House, 137-139 Brent Street
LONDON, NW4 4DJ  United Kingdom Ticker: KNBKNB
Business Summary
Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Ian T.Mattioli 61 5/9/2023 5/9/2023
Chief Executive Officer, Executive Director Avihu I.Tamir 43 2/16/2021 2/16/2021
Non-Executive Independent Vice Chairman of the Board DavidTsur 74 5/9/2023 2/16/2021
Chief Financial Officer, Company Secretary AssafVardimon 1/1/2022 1/1/2022
Non-Executive Independent Director SharonMalka 52 5/4/2023 5/4/2023

Business Names
Business Name
KNB
SOP

General Information
Number of Employees: 17 (As of 12/31/2023)
Outstanding Shares: 632,427,870 (As of 6/30/2024)
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024